🧬 Orthobiologic Regulatory Classification (FDA) Simulator

21 CFR Part 1271 — How FDA Defines and Captures Human Cells, Tissues, and Cellular/Tissue-Based Products

Before any orthobiologic product — PRP, bone marrow aspirate concentrate, adipose-derived stromal vascular fraction, amniotic tissue allografts — can be evaluated for its regulatory pathway, it must first be recognized as falling within FDA's HCT/P framework at all. This framework, built out through the "Tissue Rule" rulemakings finalized between 2001 and 2005, gives FDA authority over articles containing or consisting of human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient.

• 21 CFR Part 1271: Governing regulation (Human Cells, Tissues, and Cellular and Tissue-Based Products)
• 2001–2005: Tissue Rule finalized (three-rule regulatory framework)
• §1271.3(d): HCT/P definition section (articles from human cells or tissue)
• §1271.10–.27: Registration requirement (establishment registration & listing)

What counts as an HCT/P, and why orthobiologics are captured

FDA defines an HCT/P at 21 CFR §1271.3(d) as "articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient." This deliberately broad definition captures a wide range of orthopedic and sports-medicine products, including:

• Autologous platelet-rich plasma (PRP) — plasma centrifuged from the patient's own blood, concentrating platelets and their growth factor payload, injected back into that same patient • Bone marrow aspirate concentrate (BMAC) — marrow drawn (typically from the iliac crest), centrifuged to concentrate nucleated cells, and re-injected • Adipose-derived stromal vascular fraction (SVF) — fat tissue processed (often enzymatically) to isolate a cell pellet containing mesenchymal stromal cells and other cell types • Amniotic membrane and amniotic fluid-derived allograft products — donated birth tissue processed into injectable or membrane products • Umbilical cord blood or Wharton's jelly-derived allograft products marketed for orthopedic use

The three-part Tissue Rule framework established:

1. 21 CFR Part 1271 Subpart B — registration and listing requirements for establishments that recover, process, store, or distribute HCT/Ps 2. 21 CFR Part 1271 Subpart C — donor eligibility requirements (screening and testing for relevant communicable disease agents), primarily relevant to allograft (donor-derived) rather than autologous products 3. 21 CFR Part 1271 Subpart D — current good tissue practice (CGTP) requirements governing the methods, facilities, and controls used in manufacturing HCT/Ps to prevent contamination and cross-contamination

Importantly, being an HCT/P does not by itself determine the regulatory pathway. Every HCT/P must then be evaluated against the four criteria in §1271.10(a) to determine whether it qualifies for the lower-burden "361" pathway or defaults to full biologic/drug regulation under section 351 of the Public Health Service Act. The two determinative criteria in that test — minimal manipulation and homologous use — are examined in the next two stages of this simulation.

Minimal Manipulation — Has Processing Changed the Tissue's Original Relevant Characteristics?

The first of the two determinative §1271.10(a) criteria asks a deceptively simple question: did the manufacturing/processing steps applied to the tissue alter its original relevant biological characteristics relating to the tissue's utility for reconstruction, repair, or replacement? FDA draws a regulatory line between processing that is essentially concentrating or preparing tissue that already exists, versus processing that meaningfully transforms the biological material into something new.

• §1271.10(a)(1): Criterion citation (referencing §1271.3(f))
• Original relevant characteristics: Structural tissue standard (for reconstruction/repair/replacement)
• Biological characteristics: Cell/nonstructural standard (for growth/repair/reconstitution)
• Minimal Manipulation of HCT/Ps: 2017 FDA guidance (clarified examples & case studies)

Where the line is drawn: examples that are and are not minimal manipulation

FDA's regulation distinguishes two tests depending on tissue type:

For structural tissue (bone, cartilage, skin, blood vessels): minimal manipulation means "processing that does not alter the original relevant characteristics of the tissue relating to the tissue's utility for reconstruction, repair, or replacement."

For cells or nonstructural tissues (bone marrow, PRP, adipose tissue, cord blood): minimal manipulation means "processing that does not alter the relevant biological characteristics of cells or tissues" relating to their function in growth, repair, or reconstitution.

Generally considered minimal manipulation (frequently cited by FDA guidance and industry as consistent with the 361 pathway when other criteria are also met):

• Centrifugation to separate blood components and concentrate platelets (standard PRP preparation) • Centrifugation or filtration of bone marrow aspirate to concentrate the nucleated cell fraction (BMAC) • Cutting, grinding, or shaping of structural tissue (e.g., bone allograft) that does not change its basic structural function • Cryopreservation and thawing without other alteration • Sterilization by methods that do raise concern about affecting relevant characteristics

Generally considered more than minimal manipulation (pushing a product toward 351 regulation):

• Enzymatic digestion of adipose tissue to isolate stromal vascular fraction (SVF) — the enzymatic step breaks down the native tissue architecture, which FDA has explicitly identified as more than minimal manipulation in guidance and enforcement actions • Ex vivo culture expansion of cells (growing mesenchymal stem cells in culture to increase their number before re-implantation) • Genetic modification of cells • Combination with a non-tissue component (e.g., a scaffold or synthetic material) in a way that provides an additional function beyond the tissue's own

The 2017 FDA guidance document "Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products" and its companion "Same Surgical Procedure Exception" guidance provided detailed case examples specifically because the agency recognized substantial industry confusion (and, in some cases, deliberate mischaracterization) about where common orthobiologic processing methods fall on this spectrum.

A frequent point of confusion: concentrating platelets via centrifugation (PRP) is a physical separation process widely accepted as minimal manipulation, while using an enzyme (typically collagenase) to digest adipose tissue and release SVF cells is a chemical/biological transformation of the tissue matrix — and multiple FDA warning letters and the 2019 US Stem Cell Clinic litigation turned significantly on this exact distinction.

Homologous Use — Will the Product Perform the Same Basic Function in the Recipient as in the Donor?

The second determinative §1271.10(a) criterion asks whether the HCT/P is intended for homologous use only — meaning the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissue with an HCT/P that performs the same basic function or functions in the recipient as in the donor. This criterion is about the marketed intended use, not just the biology of the tissue itself — the same physical product can be homologous in one marketing claim and non-homologous in another.

• §1271.10(a)(2): Criterion citation (referencing §1271.3(c))
• Basic function match: Test focus (donor tissue function vs. recipient use)
• Homologous Use of HCT/Ps: 2017 FDA guidance (detailed worked examples)
• Labeling, advertising, marketing: Determined by (not just biological plausibility)

Same basic function, different anatomic site — and where marketing claims cross the line

Homologous use is evaluated primarily by looking at how a product is labeled, advertised, and marketed — what claims are made about what the product does — rather than by an abstract biological judgment alone. Key interpretive points from FDA's 2017 homologous use guidance:

• A tissue can be used at a different anatomic site than its donor site and still be homologous use, as long as it performs the same basic function. Example: PRP drawn from a patient's own peripheral blood, injected into a degenerated tendon to support the same basic wound-healing, growth-factor-signaling function platelets perform natively at any site of tissue injury, is generally considered homologous use.

• Structural tissue used to replace a structural function elsewhere in the body (e.g., bone graft used for spinal fusion) is homologous, because the basic function — providing structural support — is preserved even though the exact anatomic location differs.

Examples FDA and courts have treated as non-homologous use, pushing a product toward 351 regulation regardless of how it was processed:

• Marketing autologous or allogeneic MSC products via intravenous infusion or intra-articular injection to treat conditions such as autism spectrum disorder, amyotrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD), or general "anti-aging"/wellness indications, where the claimed therapeutic mechanism (broad anti-inflammatory, regenerative, or trophic effects across unrelated organ systems) is not the tissue's "same basic function" in the donor • Using adipose-derived cells, whose native function in the donor is structural/energy-storage and paracrine support within fat tissue, and marketing them instead for orthopedic tissue regeneration, immune modulation, or treatment of systemic autoimmune disease — a functional leap beyond adipose tissue's own basic biological role • Amniotic tissue products marketed with broad regenerative, anti-inflammatory, or "stem cell" claims for orthopedic, ophthalmologic, or aesthetic indications well beyond the tissue's original role in supporting fetal development

Because the homologous use test turns heavily on marketing claims, two clinics performing biologically identical processing of the same starting tissue can land on opposite sides of this criterion purely based on what they say the product treats — which is precisely why FDA enforcement in this space has focused so heavily on clinic websites, patient brochures, and physician marketing materials as evidence.

The Regulatory Fork — Registration-Only 361 Products vs. Full Biologic Regulation Under Section 351

Once minimal manipulation and homologous use (plus the two remaining, less frequently determinative §1271.10(a) criteria — no combination with a drug/device that affects the HCT/P's function, and either no systemic effect and dependence on living cell metabolism for a primary function, or a systemic/metabolism-dependent effect used only autologously, allogeneically in a first- or second-degree relative, or for reproductive use) are all assessed, the product resolves into one of two fundamentally different regulatory tracks.

• §1271.10(a), all 4 criteria met: 361 pathway basis ("registration-only" tissues)
• Establishment registration + listing: 361 requirements (CGTP compliance, no premarket review)
• Fails any §1271.10(a) criterion: 351 pathway basis (PHS Act §351 biological product)
• IND → clinical trials → BLA: 351 requirements (premarket safety/efficacy review)

What each pathway actually requires in practice

The 361 pathway (named for section 361 of the Public Health Service Act, implemented through 21 CFR Part 1271):

• No premarket approval or clearance required — FDA does not review safety or efficacy data before the product reaches the market • The establishment that recovers, processes, or distributes the HCT/P must register with FDA and submit a list of the HCT/Ps it handles • The establishment must comply with current good tissue practice (CGTP) requirements: donor eligibility determination (where applicable), and process controls to prevent contamination, cross-contamination, and communicable disease transmission • FDA retains inspection authority and can take enforcement action if a 361-registered establishment is found to be out of compliance, or if a product is being marketed in a way that FDA determines actually falls outside the 361 criteria • Typical genuine 361 products: same-day, minimally manipulated, homologous-use autologous PRP and BMAC used by the same physician in the same surgical/procedural encounter often also qualify for a same-surgical-procedure exception under §1271.15(b), further simplifying their regulatory posture

The 351 pathway (biological products regulated as drugs/biologics under the Public Health Service Act and the FD&C Act):

• The sponsor must file an Investigational New Drug (IND) application before beginning any clinical study of the product in humans • Clinical development proceeds through Phase 1 (safety), Phase 2 (dose-finding/preliminary efficacy), and Phase 3 (pivotal efficacy and safety) trials, similar to a small-molecule drug or conventional biologic • A Biologics License Application (BLA) must be approved by FDA — supported by substantial evidence of safety and effectiveness — before the product can be legally marketed for its intended use • Manufacturing must comply with current Good Manufacturing Practice (cGMP), a substantially more rigorous standard than CGTP • Development timelines commonly span many years and tens to hundreds of millions of dollars, similar to conventional drug development

FDA explicitly stated, through its 2017 regenerative medicine guidance framework and an extended enforcement discretion period (through May 2021) intended to give industry and clinicians time to come into compliance, that products failing the 361 criteria but continuing to be marketed without an approved BLA are being sold in violation of federal law — this is precisely the theory underlying the enforcement actions covered in the next stage.

US Stem Cell Clinic — The Landmark Case Establishing Real Consequences for Non-Compliant Orthobiologic Marketing

The clearest illustration of what happens when a clinic misclassifies its own product is United States v. US Stem Cell Clinic, LLC, decided by the U.S. District Court for the Southern District of Florida in June 2019. The case is the definitive real-world example cited throughout FDA guidance, legal literature, and professional society position statements warning physicians and patients about unproven stem cell interventions marketed outside the proper regulatory pathway.

• June 2019: Case decided (S.D. Fla., permanent injunction granted)
• Adipose-derived SVF: Product at issue (enzymatically digested, non-homologous claims)
• More than minimal manipulation: Court finding (+ non-homologous use = 351 drug)
• Patient blindness: Reported adverse outcome (from intraocular/intravitreal injection)

What the clinic did, what the court found, and why it matters for every orthobiologic practice

US Stem Cell Clinic (formerly known as Bioheart, operating in Sunrise, Florida) processed patients' own adipose tissue by enzymatically digesting it to isolate stromal vascular fraction (SVF), then marketed and administered the resulting cell product to treat a wide range of serious conditions — including Parkinson's disease, chronic obstructive pulmonary disease, and macular degeneration — via routes including intravenous infusion and, notably, intraocular/intravitreal injection.

Why the product failed to qualify for the 361 pathway, on both determinative criteria simultaneously:

1. More than minimal manipulation: the court found that enzymatic digestion of adipose tissue to release the SVF cell population altered the tissue's original relevant characteristics — it was not a simple physical separation like centrifuging PRP, but a chemical/enzymatic transformation of the native tissue matrix.

2. Non-homologous use: SVF's basic function in native adipose tissue (structural, energy storage, local paracrine support) bears no resemblance to the claimed therapeutic uses being marketed — treating neurodegenerative disease, pulmonary disease, or macular degeneration via injection is a functional application entirely disconnected from the tissue's basic function in the donor.

Because the product failed both criteria, the court held it was a drug and biological product requiring FDA approval under section 351 of the PHS Act and the FD&C Act — approval the clinic never obtained, and had never submitted an IND application to pursue. The court entered a permanent injunction barring the clinic from marketing its SVF product until it obtained proper FDA approval, rejecting the clinic's argument that its product should be treated as a 361 tissue product exempt from premarket review.

The case gained particular public attention because of reported adverse events: patients who received intravitreal (into the eye) injections of the SVF product for macular degeneration experienced severe complications, including several cases of permanent blindness — a stark illustration of the patient-safety rationale behind requiring premarket safety and efficacy review for products that fail the 361 criteria.

Broader significance for the orthobiologics field:

• The case is routinely cited by orthopedic and sports medicine professional societies (e.g., AAOS, AOSSM) in position statements urging physicians to understand and correctly classify the biologics they use in practice • It illustrates that FDA enforcement discretion is not indefinite immunity — the agency explicitly signaled (in its 2017 regenerative medicine framework) a defined transition period after which non-compliant products would face active enforcement, and followed through • It underscores that regulatory classification depends on the specific combination of processing method and marketing claim for a given product — a clinic offering compliant, minimally manipulated, homologous-use PRP for tendinopathy is on fundamentally different legal footing than one offering enzymatically-digested SVF marketed for unrelated systemic disease, even if both operate under the broad "orthobiologics" or "regenerative medicine" umbrella

The core lesson for any orthobiologic practice is that "stem cell clinic" is not a regulatory category — every individual product and every individual marketed use claim must independently satisfy both the minimal manipulation and homologous use criteria to remain in the lower-burden 361 pathway. Getting either criterion wrong does not produce a minor compliance gap; it reclassifies the product as an unapproved biologic drug, exposing the clinic to injunctions, seizure actions, and civil or criminal liability under 21 U.S.C. §331 and §333.